Fmr LLC Immunity Bio, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Fmr LLC holds 11,760 shares of IBRX stock, worth $40,219. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,760

Previous 19,140 38.56%

Holding current value

$40,219

Previous $102,000 27.45%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$4.82 - $9.15 $35,571 - $67,527	-7,380 Reduced 38.56%	11,760 $74,000
Q1 2024 May 13, 2024	BUY	$3.23 - $6.17 $6,220 - $11,883	1,926 Added 11.19%	19,140 $102,000
Q4 2023 Feb 13, 2024	BUY	$1.25 - $5.21 $2,916 - $12,154	2,333 Added 15.68%	17,214 $86,000
Q3 2023 Nov 13, 2023	BUY	$1.29 - $3.1 $12,576 - $30,221	9,749 Added 189.96%	14,881 $25,000
Q2 2023 Aug 11, 2023	BUY	$1.53 - $6.41 $342 - $1,435	224 Added 4.56%	5,132 $14,000
Q1 2023 May 11, 2023	SELL	$1.35 - $4.78 $6,124 - $21,686	-4,537 Reduced 48.04%	4,908 $8,000
Q4 2022 Feb 13, 2023	SELL	$4.35 - $6.77 $1,800 - $2,802	-414 Reduced 4.2%	9,445 $47,000
Q3 2022 Nov 10, 2022	BUY	$3.65 - $6.43 $3,102 - $5,465	850 Added 9.44%	9,859 $49,000
Q2 2022 Aug 12, 2022	SELL	$2.68 - $6.14 $269,139 - $616,609	-100,425 Reduced 91.77%	9,009 $33,000
Q1 2022 May 13, 2022	BUY	$5.05 - $7.53 $552,641 - $824,038	109,434 New	109,434 $614,000
Q3 2021 Nov 15, 2021	SELL	$9.17 - $14.24 $917 - $1,424	-100 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$13.41 - $22.4 $1,341 - $2,240	100 New	100 $1,000

Others Institutions Holding IBRX

# of Institutions

216

Shares Held

63.3M

Call Options Held

1.43M

Put Options Held

4.12M

View Full List

About ImmunityBio, Inc.

Ticker IBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 400,304,000
Market Cap $1.37B
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...

More about IBRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account